Last reviewed · How we verify
Betalone (MEPREDNISONE)
Betalone (meprednisone) is a glucocorticoid receptor-targeting small molecule developed by Schering, which is still owned by the company. It was FDA-approved in 1978 for various indications. Betalone is an off-patent medication with no active Orange Book patents, meaning it can be manufactured and sold generically. Despite this, there are currently no generic manufacturers. As an off-patent medication, its commercial status is uncertain.
At a glance
| Generic name | MEPREDNISONE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | meprednisone |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
Common side effects
Key clinical trials
- Methylprednisolone Combined Electric-acupuncture on Cognitive Function (PHASE1,PHASE2)
- Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betalone CI brief — competitive landscape report
- Betalone updates RSS · CI watch RSS
- Merck & Co. portfolio CI